Introduction
Resistance to conventional antibiotics is a significant threat to global public health. [1] As an alternative approach, host-defense peptides (HDPs) have emerged as promising antibiotic agents. HDPs are present in virtually all life forms, acting as the first line of defense against microbial infection. [1, 2] The current paradigm is that HDPs initially adopt globally amphipathic structures, which in turn disrupt negatively charged bacterial membranes. [1, 2] Intriguingly, in addition to direct bacterial killing, some HDPs are reported to be able to modulate the innate immune response by antagonizing Toll-like receptors (TLRs). [3] Immunomodulatory HDPs suppress production of harmful proinflammatory cytokines, thereby preventing complications from infection. [1] For instance, the human cathelicidin LL-37 can inhibit the induction of tumor necrosis factor-a (TNF-a) by Gram-positive and Gram-negative bacterial infections. [4] Despite their promising potential, HDPs face obstacles for further development due to their susceptibility to protease degradation. [1] There is significant interest in the development of unnatural mimics of HDPs, including peptoids, [5] b-peptides, [6] and other classes of oligomers and polymers. [7] Antimicrobial peptidomimetics function similarly to HDPs in their ability to assume globally amphipathic structures, embracing segregated hydrophobic and cationic patches that facilitate bacterial membrane disruption. We have previously reported a group of unnatural HDP mimics, a-AApeptides (N-acylated-N-aminoethyl peptides), as effective antimicrobial agents against various bacterial strains. [7h, i] Further lipidation has been shown to improve the antimicrobial activities of a-AApeptides and reduce their antibiotic resistance.
[7i] Herein, we report the development of modified a-AApeptides through simultaneous lipidation and cyclization. These novel cyclic lipo-a-AApeptides demonstrate significantly improved potency and broad-spectrum activity against a range of clinically relevant Gram-positive and Gram-negative bacteria. Furthermore, the lead cyclic lipo-a-AApeptide is the first of its kind shown to mimic some HDPs by antagonizing TLR4-induced nuclear factor kappalight-chain-enhancer of activated B cells (NF-kB) and nitric oxide (NO) signaling responses, as well as inhibiting production of proinflammatory cytokines such as TNF-a.
[4] The linear analogue of the lead cyclic lipo-a-AApeptide shows weaker antimicrobial and inferior anti-inflammatory activity, indicating that both lipidation and cyclization are critical for the dual functionality. As such, cyclic lipo-a-AApeptides could emerge as a new class of antibiotic agents with both direct bacterial toxicity and immunomodulation ability.
Results and Discussion
Our current design is based on the finding that cyclization decreases sequence flexibility and stabilizes amphipathic structures, leading to antimicrobial agents with improved potency.
[7e, f, j] Clinically approved cyclic lipopeptides daptomycin [8] and polymyxin [9] are used to treat infections caused by GramHerein we describe the development of a new class of antimicrobial and anti-inflammatory peptidomimetics: cyclic lipo-aAApeptides. They have potent and broad-spectrum antibacterial activity against a range of clinically relevant pathogens, including both multidrug-resistant Gram-positive and Gram-negative bacteria. Fluorescence microscopy suggests that cyclic lipo-a-AApeptides kill bacteria by disrupting bacterial membranes, possibly through a mechanism similar to that of cationic host-defense peptides (HDPs). Furthermore, the cyclic lipo-aAApeptide can mimic cationic host-defense peptides by antagonizing Toll-like receptor 4 (TLR4) signaling responses and suppressing proinflammatory cytokines such as tumor necrosis factor-a (TNF-a). Our results suggest that by mimicking HDPs, cyclic lipo-a-AApeptides could emerge as a new class of antibiotic agents that directly kill bacteria, as well as novel antiinflammatory agents that act through immunomodulation.
positive and Gram-negative bacteria, respectively. However, the development of antimicrobial peptidomimetics with lipocyclic motifs is rare. We have previously shown that antimicrobial a-AApeptides can be designed in a straightforward manner by joining a-AApeptide building blocks together. These building blocks assume amphipathic conformations upon interaction with bacterial membranes. [7h, i] Thus, we hypothesize that cyclic a-AApeptides containing amphipathic aAApeptide building blocks and a membrane-directing lipid tail will lead to improved antimicrobials.
Previous studies have shown that both the number of amphipathic building blocks and the length of the lipid tails affect antimicrobial activity. [7h, i] This is because the specific interactions between bacterial membranes and peptide sequences are largely governed by overall hydrophobicity and cationic charges. In addition, the length of the lipid tails is believed to be important for penetrating bacterial membranes.
[7h, i] Thus, a series of cyclic a-AApeptides containing different numbers of amphipathic a-AApeptide building blocks and different lengths of lipid tails were prepared following the synthetic route shown in Scheme 1.
We designed amphipathic a-AApeptide building blocks that possess a cationic Lys side chain and hydrophobic lipid tails of varying lengths. Thus, different lipid tails can be conveniently introduced to cyclic a-AApeptides on the solid phase. C 6 -C 16 alkyl tails are most commonly observed in lipopeptide antibiotics.
[1] Therefore, we chose C 6 , C 12 , and C 16 lipid tails to study their impact on the antimicrobial activity of cyclic lipo-a-AApeptides. The synthesis was accomplished by first attaching an a-AApeptide building block to the solid support, followed by the addition of an allyl carboxylate ester-containing AApeptide building block, which enables cyclization directly on the solid phase.
[7j] After the a-AApeptide oligomers were assembled, the allyl protecting group was removed by using Pd(PPh 3 ) 4 . Following removal of the Fmoc group, the sequence was cyclized in the presence of PyBop. Such an approach circumvents the need to cyclize the sequences in solution after cleavage from the solid support, greatly simplifying the purification process.
We then tested these sequences against several clinically relevant, multidrug-resistant bacteria, including both Gram-positive and Gram-negative strains (Table 1 ). Both the number of cationic charges and the extent of hydrophobicity have been shown to be important for potent antimicrobial activity. Cyclic lipo-a-AApeptide 1, which contains three amphiphilic building blocks in the ring, as well as a C 6 lipid tail, did not show any antimicrobial activity under the tested conditions. However, with the same ring structure, replacement of the C 6 lipid tail in 1 with a C 12 lipid tail yielded 2, which showed good activity against Gram-positive bacteria. Further increase of the lipid tail length to C 16 led to 3, which demonstrated excellent potency against both Gram-positive and Gram-negative bacteria. The relationship between tail length and potency could suggest that short lipid tails cannot penetrate bacterial membranes. This is especially relevant for Gram-negative bacteria, which have both outer and inner membranes. A similar correlation between lipid tail length and potency was also observed for 5 and 6. Additionally, it seems that increasing ring size does not significantly affect antimicrobial activity, as seen with 3, 4, and 6. In fact, 3 has a smaller ring size and has the most potent antimicrobial activity against Gram-positive bacteria. Our results indicate that we might have reached an optimal ring size. This is also consistent with the findings that many natural cyclic peptide antimicrobial agents also contain six to eight amino acid residues in their ring structures. [8, 9] When compared to the previously developed linear a-AApeptide NB-119-2 and the HDP analogue pexiganan, this new class of cyclic lipo-a-AApeptides is more potent.
The capability of cyclic lipo-a-AApeptides to mimic HDPs and disrupt bacterial membranes was assessed by fluorescence microscopy. MRSA ATCC 33591 was stained with the membrane-permeable dye 4',6-diamidino-2-phenylindole (DAPI) and the non-membrane-permeable dye propidium iodide (PI) in the presence or absence of cyclic lipo-a-AApeptide 3 ( Figure 1 ). Upon treatment with 3, both DAPI and PI were able to permeate MRSA membranes, indicating perturbed integrity. The aggregation of bacteria after treatment might be due to the loss of membrane potential, [7h, k] consistent with the observation of membrane disruption.
In addition to potent antimicrobial activity, an interesting behavior of HDPs is that they might repress inflammation, [4] providing a new approach for the treatment of bacteriuminduced inflammatory disorders. Our recent data have shown that certain HDP-mimicking g-AApeptides also have the similar functions. [11] Therefore, as structural and functional mimics of HDPs, cyclic lipo-a-AApeptides are proposed to harness the innate immune system in a similar fashion. As such, we investigated the ability of 3 to modulate immune responses through TLR4 signaling. TLRs are evolutionarily conserved type I transmembrane proteins responsible for the inflammatory response to invasive pathogens. The native ligand for TLR4 is lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls.
[4b] Through TLR4, LPS activates the NF-kB signaling pathway and downstream production of cytokines such as TNF-a. Currently, there is great interest in developing molecules to modulate TLR signaling as therapeutic candidates for immunity malfunctions. As an elegant example, Tew and co-workers demonstrated that antimicrobial agents might exhibit immunomodulatory activities. [10a, 12] To test the ability of cyclic lipo-a-AApeptides to modulate TLR4 signaling, we first tested the inhibitory effects of the lead compound, 3, in a nitric oxide (NO) production assay (Figure 2 A) . [13] NO produced in the downstream inflammatory signaling cascade for all TLRs plays an important role in immunological processes such as the generation of free radical bacteri- Figure 1 . Fluorescence micrographs of MRSA treated with 5 mg mL À1 cyclic lipo-a-AApeptide 3 for 2 h. A1) control, no treatment, DAPI-stained; A2) control, no treatment, PI-stained; A3) control, no treatment, merged view. B1) 3 treatment, DAPI-stained; B2) treatment with 3, PI-stained; B3) treatment with 3, merged view. (16) 20 (13) 12 (8) 12 (8) 12 (8 (5) 12 (9) 10 (6) 4 (2) 8 (5) 250 (153) pexiganan --8 (3) 16 (6) 8 (3) 32 (12) 16 (6) 120 (45) [a] The minimum inhibitory concentration (MIC) is the lowest concentration that completely inhibits growth after 20 h.
[b] HC 50 is the concentration causing 50 % hemolysis. NB-119-2 [7i] and pexiganan [10] are listed for comparison.
al toxins and regulation of phagocytosis. [14] RAW 264.7 murine monocyte macrophage cells were treated with varying concentrations of 3 in the presence of 20 ng mL À1 LPS. As shown in Figure 3 , 3 is capable of inhibiting TLR4-induced NO production in a dose-dependent fashion, with an IC 50 value of (3.06 AE 0.21) mm. Importantly, 3 showed negligible cytotoxicity up to 100 mm (Figure 2 B) , confirming that its TLR4 suppression is not due to cytotoxicity.
[15]
To further confirm the effect of 3 on TLR signaling, a previously established secreted embryonic alkaline phosphatase (SEAP) assay was used to assess NF-kB activation in TLR4-overexpressing human embryonic kidney (HEK293) cells. [16] NF-kB transcription is directly correlated to TLR4 activation, as signaling results in NF-kB nuclear translocation. [17] Compound 3 inhibited NF-kB with an IC 50 value of (2.27 AE 0.08) mm (Figure 3 A) . Furthermore, production of the proinflammatory cytokine TNFa was also inhibited, with a comparable IC 50 value (Figure 3 B) , confirming the inflammation-suppressing effects of 3. As TNFa dysregulation importantly contributes to medical conditions such as systemic lupus erythematosus and multiple cancers, [18] cyclic lipo-a-AApeptides could provide a group of novel candidates for the treatment of these diseases.
We also investigated if cyclization is critical for anti-inflammatory activity by comparing 3 with its linear analogue, 3-linear. Interestingly, the ability of 3-linear to decrease NO production was comparable to that of 3 (Figure S4 B in the Supporting Information), whereas its inhibition of NF-kB and TNFa is significantly less potent ( Figures S5 and S6) . These results suggest that although linear and cyclic AApeptides do not behave identically, both possess anti-inflammatory activity. As such, we conclude that cyclization is not required to suppress inflammation. However, 3-linear shows much decreased antimicrobial activity when compared to 3 ( Figure S4 A), suggesting that cyclization is more critical for antimicrobial activity than anti-inflammatory activity.
It is known that nonpeptidic antimicrobial agents suppress TLR signaling by binding specific TLR ligands (e.g., LPS). [10a, 12] By contrast, cyclic lipo-a-AApeptides appear to function through a different mechanism. In our experiments, both pretreatment and cotreatment with 3 resulted in complete inhibition of NO production at 10 mm. Our data suggest that cyclic lipo-a-AApeptides reduce inflammatory responses by using a novel mechanism, while simultaneously fighting bacterial infection.
Conclusions
In summary, we report a new class of antimicrobial and anti-inflammatory peptidomimetics, cyclic lipo-a-AApeptides, which mimic the structures and functions of HDPs. These cyclic lipoa-AApeptides can potently arrest the growth of multidrugresistant Gram-negative and Gram-positive bacteria. Furthermore, they can modulate immune responses by strongly antagonizing TLR4 signaling and suppressing LPS-induced production of proinflammatory cytokines. Here we report not only the design and synthesis of an unprecedented cyclic lipo version of a-AApeptides but also the first example of a-AApeptides that display both potent antimicrobial and anti-inflammatory activity. Cyclic lipo-a-AApeptides could serve as a proofof-concept for immunomodulatory antimicrobial peptidomimetics that do not bind to an extracellular ligand but instead directly interact with components of the TLR signaling cascade. As the mechanistic nature of HDPs remains an outstanding problem in the field, these cyclic lipo-a-AApeptides might help us to understand an alternative mechanism for how HDPs function.
Experimental Section
Solid-phase synthesis, purification and characterization of cyclic lipo-a-AApeptides: A standard Fmoc chemistry protocol for solidphase synthesis was used to synthesize lipidated cyclic a-AApeptides on a Burell Wrist-Action shaker on Rink amide resin using peptide vessels ( Figure S2) . [7h-j, 19] Each coupling cycle consisted of Fmoc deprotection with 20 % piperidine/DMF, 6 h coupling with 2 equiv of building blocks in the presence of 4 equiv of diisopropylcarbodiimide (DIC) and 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (DhbtOH) in DMF. Firstly, the lipidated building block was attached to the solid phase support, followed by coupling with the building blocks using standard Fmoc chemistry. After the desired sequence was assembled, the allyl group was removed by usage of Pd(PPh 3 ) 4 (0.2 equiv) and PhSiH 3 (10 equiv) in CH 2 Cl 2 for 2 h (repeated twice). The Fmoc group was then removed, and intramolecular cyclization was achieved by PyBop/HOBt/DIEA/DMF. Lastly, the resin was transferred into a 4 mL vial, and the cyclic lipo-a-AApeptide was cleaved from the solid support by TFA/ CH 2 Cl 2 /triisopropylsilane (50:48:2, v/v) over 5 h. The solvent was evaporated, and the residues were analyzed and purified by a Waters HPLC system on analytical (1 mL min
À1
) and preparative (20 mL min À1 ) modules, respectively. The purities of cyclic lipo-aAApeptides (> 95 %) were determined by analytical HPLC.
Antimicrobial assay for MIC determination: The bacterial strains used to test the efficacy of cyclic lipo-a-AApeptides included multidrug-resistant Staphylococcus epidermidis (RP62A), vancomycinresistant Enterococcus faecalis (ATCC 700802), methicillin-resistant Staphylococcus aureus (ATCC 33591), Klebsiella pneumoniae (ATCC 13383), and multidrug-resistant Pseudomonas aeruginosa (ATCC 27853). The antimicrobial activities of the cyclic lipo-a-AApeptides developed were determined by the serial dilution method. Bacterial cells were grown overnight at 37 8C in 5 mL medium, after which a bacterial suspension of approximately 10 6 CFU mL À1 in Luria broth or trypticase soy was prepared, ensuring that the bacterial cells were in the mid-logarithmic phase. Aliquots of the bacterial suspension (50 mL) were added to 50 mL of medium containing the cyclic lipo-a-AApeptides, for a total volume of 100 mL in each well. The cyclic lipo-a-AApeptides were dissolved in PBS buffer in twofold serial dilutions. The concentration range used for peptides was 25 to 0.5 mg mL À1 . The 96-well plates were incubated at 37 8C for about 20 h, and the optical density (OD) was measured at a wavelength of 600 nm. The lowest concentration at which complete inhibition of bacterial growth is observed is defined as the minimum inhibitory concentration (MIC). The experiments were repeated three times, each time in duplicate.
Hemolysis assay: Freshly drawn human red blood cells (hRBCs) were used for the assay. The blood sample was washed with PBS buffer several times and centrifuged at 700 g for 10 min until a clear supernatant was observed. The hRBCs were resuspended in 1 PBS to get a 5 % (v/v) suspension, which was used to perform the assay. Twofold serial dilutions of cyclic lipo-a-AApeptides were prepared in PBS buffer. Concentrations ranging from 250 mg mL À1 to 1.56 mg mL À1 were tested by adding the cyclic lipo-a-AApeptides solutions to sterile 96-well plates to make up to a total volume of 50 mL in each well. Then, 50 mL of 5% (v/v) hRBC solution was added to achieve a total volume of 100 mL in each well. The 0 % hemolysis point and 100 % hemolysis point were determined in 1 PBS and 0.2 % Triton-X-100, respectively. The 96-well plate was incubated at 37 8C for 1 h and centrifuged at 3500 rpm (Rotor: Sorvall Heraeus 6444) for 10 min. The supernatant (30 mL) was then diluted with 1 PBS (100 mL), and hemoglobin was detected by measuring the OD 360 with a Biotek Synergy HT microtiter plate reader. Percent hemolysis = (Abs sample ÀAbs PBS )/(Abs Triton ÀAbs PBS ) 100. Peptide concentrations corresponding to 50 % hemolysis were determined from the dose-response curves. The experiments were repeated three times, each time in duplicate.
Fluorescence microscopy: A double staining method with DAPI (4',6-diamidino-2-phenylindole dihydrochloride, Sigma, > 98 %) and PI (propidium iodide, Sigma) as fluorophores was used to visualize and differentiate between viable and dead S. aureus (ATCC 33591) cells. DAPI, being a double-stranded DNA binding dye, stains all bacterial cells irrespective of their viability. Ethidium derivatives such as propidium iodide (PI) are capable of passing through only damaged cell membranes and intercalating with the nucleic acids of injured and dead cells to form a bright red fluorescent complex. Bacterial cells were grown until they reached mid-logarithmic phase, and then cells (2 10 3 ) were incubated with the cyclic lipoa-AApeptide 3 at 5 mg mL À1 for 4 h. The cells were then pelleted by centrifugation at 3000 g for 15 min. The supernatant was decanted, and the cells were washed with 1 PBS several times and incubated with PI (5 mg mL À1 ) in the dark for 15 min at 0 8C. Excessive PI was removed by washing the cells several times with 1 PBS. Lastly, the cells were incubated with DAPI (10 mg mL À1 in water) for 15 min in the dark at 0 8C. Then, excessive DAPI solution was removed, and the cells were washed with 1 PBS. Controls were treated following the exactly same procedure but in the absence of 3. The bacteria were examined by using a Zeiss Axio Imager Z1optical microscope (100 ).
Fluorescent detection of nitric oxide: RAW 264.7 (mouse leukemic monocyte macrophage cell line) cells were grown in RPMI 1640 medium with 10 % fetal bovine serum (FBS), 1 % penicillin/streptomycin, and 1 % l-glutamine. On day one, cells were plated in a 96-well plate at 75 000 cells per well in complete RPMI 1640 medium. Cells were grown overnight at 37 8C and 5 % CO 2 in a humidified incubator. On day 2, the medium was removed, and cells were placed in unsupplemented RPMI 1640 medium. LPS (20 ng mL À1 ) and the appropriate concentration of AApeptides were added to a final volume of 200 mL. All stock solutions of AApeptides were prepared in PBS as 20 mm stocks and then diluted to the desired concentration with PBS. There were PBS controls in each experiment. Plates were then incubated for 24 h after treatment. Following incubation, 100 mL of medium was removed from each well and added to a flat black 96-well microfluor plate (Thermo Scientific). 2,3-Diaminonamthalene (10 mL, 0.05 mg mL À1 ) in HCl (0.62 m) was added to the medium, and the mixture was incubated for 20 min in the dark. The reaction was quenched with NaOH (3.0 m, 5 mL), and the plate was read on a DTX880 plate reader (Beckman Coulter, CA, USA). Data were collected with excitation at 360 nm and emission at 430 nm. Data were normalized with the ligandonly control as 100 % activation and the untreated cells as 0 % Secreted embryonic alkaline phosphatase (SEAP) reporter of NFkB transcription: HEK293 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) with 10 % FBS, 1 % penicillin/streptomycin, and 1 % l-glutamine. HEK293 cells were stably transfected with human TLR4, as well as the required accessory proteins MD-2 and CD14. Additionally, the cells possess an optimized alkaline phosphatase reporter gene under the control of a NF-kB-inducible promoter. [20] On day one, cells were plated in a 96-well plate at 40 000 cells per well in complete DMEM medium. Cells were grown overnight at 37 8C and 5 % CO 2 in a humidified incubator. On day 2, medium was removed, and cells were placed in Optimem + 0.5 % FBS medium. LPS (20 ng mL
) and the appropriate concentration of AApeptides were added to a final volume of 200 mL. All stock solutions of AApeptides were prepared as 20 mm stocks in PBS and then diluted to the desired concentration with PBS. There were PBS controls in each experiment. Plates were then incubated for 24 h after treatment. Following incubation, the medium was assayed by using the Phospha-Light SEAP Reporter Gene Assay System (Applied Biosystems) per the manufacturer's instructions. The plate was read on a DTX880 plate reader (Beckman Coulter). Data were collected with luminescence at 430 nm. Data were normalized with the ligand-only control as 100 % activation and the untreated cells as 0 % activation. Enzyme-linked immunosorbent assay (ELISA) detection of TNFa: RAW 264.7 cells were grown in RPMI 1640 medium with 10 % FBS, 1 % penicillin/streptomycin, and 1 % l-glutamine. On day 1, cells were plated in a 96-well plate at 75 000 cells per well in complete RPMI 1640 medium. Cells were grown overnight at 37 8C and 5 % CO 2 in a humidified incubator. On day 2, the medium was removed, and cells were placed in unsupplemented RPMI 1640 medium. LPS (20 ng mL
) and the appropriate concentration of AApeptides were added to a final volume of 200 mL. We prepared all stock solutions of AApeptides as 20 mm stocks in PBS and then diluted to the desired concentration with PBS. There were PBS controls in each experiment. Plates were then incubated for 24 h after treatment. Following incubation, samples were assayed for TNFa per the method outlined in the BD Biosciences Mouse TNF (Mono/Mono) ELISA Set (BD Biosciences, CA, USA). The plate was read on a DTX880 plate reader (Beckman Coulter Crystal violet toxicity assay: Cells that were treated with compound for NO experimentation were also tested for compound toxicity by using crystal violet stain. The medium was decanted, and the cells were fixed for 20 min in paraformaldehyde (4 %). After fixing, the formaldehyde was removed, and cells were incubated for one hour with crystal violet stain (0.05 %). After incubation, cells were rinsed with deionized water to remove excess stain and reconstituted in 100 % MeOH for 10 min. The plate was read on a DTX880 plate reader (Beckman Coulter). Data were collected with absorbance at 535 nm. Data were normalized with the untreated cells control as 100 % survival and 100 % DMSO as 0 % survival. Fold inhibition = [(sample 535 nm À100 % DMSO 535 nm )/(untreated cells 535 nm À100 % DMSO 535 nm )].
